Schizophrenia Schizophrenia, Melatonin, Risperidone, Cognitive function
Conditions
Interventions
22 participants included in treatment group receiving risperidone 4-6 mg/day + adjuvant melatonin 5 mg/day for 8 weeks, patients underwent follow-up with cognitive function assessment using the MoCA-I
Experimental Drug,Placebo Comparator Drug
Sponsors
None listed
Eligibility
Sex/Gender
Male
Age
25 Years to 45 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria were : 1. patients diagnosed with schizophrenia according to ICD 10 2. Aged 20-45 years, with the onset of the disease <1 year 3. Had passed the acute phase (PANSS-EC score <15) 4. Had disturbed sleep (Pittsburgh Sleep Quality Index score> 5) 5. Were able and willing to participate in the study, and received risperidone therapy 4-6 mg/day
Exclusion criteria
Exclusion criteria: The exclusion criteria were : 1. Having organic comorbidities 2. Having a history of drug use in the last 6 months before hospitalization 3. Using anti-inflammatory drugs and antibiotics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive Function Baseline and week 8 Numeric / Total Score of cognitive function using the Montreal Cognitive Assessment- Indonesian Version | — |
Secondary
| Measure | Time frame |
|---|---|
| Melatonin serum level Baseline and week 8 Numeric was evaluated by blood specimens were taken from the median cubital vein, centrifuged, and then examined using an ELISA Kit (Humat MT, Elabsience) according to the protocol | — |
Countries
Indonesia
Contacts
Public ContactChristian Junaedi
Hasanuddin University
Outcome results
None listed